NASDAQ:TXMD TherapeuticsMD (TXMD) Stock Price, News & Analysis $1.40 -0.06 (-4.11%) (As of 05:13 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About TherapeuticsMD Stock (NASDAQ:TXMD) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TherapeuticsMD alerts:Sign Up Key Stats Today's Range$1.36▼$1.4750-Day Range$1.46▼$1.7952-Week Range$1.36▼$3.07Volume26,512 shsAverage Volume17,466 shsMarket Capitalization$16.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.Read More… Bill Gates’s Next Big AI Bet: Stargate (Ad)In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.I believe we are about to do it again with this new AI project called Stargate TherapeuticsMD Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks15th Percentile Overall ScoreTXMD MarketRank™: TherapeuticsMD scored higher than 15% of companies evaluated by MarketBeat, and ranked 924th out of 973 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for TherapeuticsMD. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioTherapeuticsMD has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about TherapeuticsMD's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.26% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently increased by 26.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTherapeuticsMD does not currently pay a dividend.Dividend GrowthTherapeuticsMD does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.26% of the float of TherapeuticsMD has been sold short.Short Interest Ratio / Days to CoverTherapeuticsMD has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in TherapeuticsMD has recently increased by 26.38%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.07 News SentimentTherapeuticsMD has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for TherapeuticsMD this week, compared to 0 articles on an average week. Company Ownership1.7 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, TherapeuticsMD insiders have bought more of their company's stock than they have sold. Specifically, they have bought $2,040.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 2.30% of the stock of TherapeuticsMD is held by insiders.Percentage Held by InstitutionsOnly 30.74% of the stock of TherapeuticsMD is held by institutions.Read more about TherapeuticsMD's insider trading history. Receive TXMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter. Email Address TXMD Stock News HeadlinesTherapeuticsMD Shifts Focus with Lower Q3 LossesNovember 15 at 12:00 AM | markets.businessinsider.comTherapeuticsMD Reports Reduced Losses Amid Strategic ShiftNovember 15 at 12:00 AM | markets.businessinsider.comTop "Sleeping Giant" Crypto In The Market NowTop "Sleeping Giant" Crypto In The Market Now We're looking at potential returns that could rewrite your financial future. November 15, 2024 | Crypto 101 Media (Ad)TherapeuticsMD Announces Third Quarter 2024 Financial ResultsNovember 13 at 2:01 AM | finance.yahoo.comTherapeuticsMD Inc. stock remains steady Monday, underperforms marketNovember 12 at 6:11 AM | marketwatch.comTherapeuticsMD (NASDAQ:TXMD) Now Covered by Analysts at StockNews.comNovember 12 at 4:32 AM | americanbankingnews.comTherapeuticsMD (NASDAQ:TXMD) Stock, Option ChainNovember 6, 2024 | benzinga.comTherapeuticsMD Inc. stock remains steady Wednesday, underperforms marketNovember 6, 2024 | marketwatch.comSee More Headlines TXMD Stock Analysis - Frequently Asked Questions How have TXMD shares performed this year? TherapeuticsMD's stock was trading at $2.25 on January 1st, 2024. Since then, TXMD stock has decreased by 36.9% and is now trading at $1.4199. View the best growth stocks for 2024 here. How were TherapeuticsMD's earnings last quarter? TherapeuticsMD, Inc. (NASDAQ:TXMD) posted its earnings results on Monday, August, 14th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.07) by $0.17. The company had revenue of $0.44 million for the quarter. TherapeuticsMD had a negative net margin of 207.77% and a negative trailing twelve-month return on equity of 14.08%. When did TherapeuticsMD's stock split? Shares of TherapeuticsMD reverse split on the morning of Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. How do I buy shares of TherapeuticsMD? Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TherapeuticsMD own? Based on aggregate information from My MarketBeat watchlists, some other companies that TherapeuticsMD investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), Marinus Pharmaceuticals (MRNS), AUO (AUOTY) and The RMR Group (RMR). Company Calendar Last Earnings8/14/2023Today11/15/2024Fiscal Year End12/31/2024Next Earnings (Estimated)4/04/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TXMD Previous SymbolNYSEMKT:TXMD CUSIPN/A CIK25743 Webwww.therapeuticsmd.com Phone(561) 961-1900Fax561-431-3389Employees420Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,280,000.00 Net Margins-207.77% Pretax Margin-251.25% Return on Equity-14.08% Return on Assets-9.61% Debt Debt-to-Equity RatioN/A Current Ratio2.03 Quick Ratio2.03 Sales & Book Value Annual Sales$1.30 million Price / Sales12.59 Cash FlowN/A Price / Cash FlowN/A Book Value$2.35 per share Price / Book0.60Miscellaneous Outstanding Shares11,530,000Free Float11,267,000Market Cap$16.37 million OptionableOptionable Beta1.14 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report This page (NASDAQ:TXMD) was last updated on 11/15/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredNvidia’s world of pain awaitsThe Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TherapeuticsMD, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TherapeuticsMD With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.